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Specificity of the volume-sensitive sodium pump inhibitor isolated from
human peritoneal dialysate in chronic renal failure. Compromised renal
function predisposes to volume-dependent hypertension. Increased
plasma levels of a sodium pump inhibitor as a possible pathogenetic factor
have been demonstrated by many investigators in such patients, but efforts
to identify the responsible agent have led to many, diverse candidates. Our
premise in this study is that candidacy must depend on the satisfaction of
rigorous criteria, including a specific action of the agent on the sodium
pump. These criteria included reversibility, concentration dependence,
receptor mediation, and an action at the appropriate step in the enzyme
cycle. These criteria were applied to a potent [Na,K]ATPase inhibitor we
have identified in the peritoneal dialysate of patients with chronic renal
failure, present only during extracellular fluid volume expansion, the levels
of which are correlated with the blood pressure rise that results from
excessive NaCI and water intake. In microsomes that contained both
[Na,K]ATPase and other ATPases, this candidate inhibited only the Na
and K dependent, ouabain-sensitive ATPase. It displaced ouabain from
the cardioglycoside binding site and its binding was linked to inhibition.
Inhibition was produced by slowing the pump's dephosphoiylation step,
the exact action of all cardioglycosides. Finally, the candidate cross reacted
with a digoxin Fab fragment and this Fab reversed its inhibition of
[Na,KIATPa5e. Together, these experiments demonstrate that the PD
candidate specifically, and reversibly, inhibits the sodium pump via the
cardioglycoside binding site, and hence, meets this crucial criterion for
candidacy.
As renal disease compromises kidney function, a volume de-
pendent form of hypertension commonly arises [1, 2]. Although
the pathogenesis of this hypertension is probably complex, many
investigators have demonstrated in such patients a circulating
inhibitor of the sodium pump, which is capable of causing
vasoconstriction and would appear to link volume status to blood
pressure [3—13]. Studies in animal models of salt sensitive hyper-
tenstion have consistently produced similar findings [14—18].
Despite repeated and consistent demonstrations of a correlation
between renal function, volume status, sodium pump inhibitory
activity and blood pressure, hypotheses related to this inhibitor
have not achieved universal acceptance. The controversy contin-
ues, in part, for at least two reasons: First, patients with reduced
renal function accumulate a wide variety of compounds that may
not be relevant. Second, many diverse compounds have been
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claimed as the responsible factor, often supported by a very
limited range of scientific criteria, creating confusion and skepti-
cism [19—22]. Indeed, a wide range of physiologic compounds
when present at high concentrations may affect [Na,KIATPase
activity, but act in a non-specific manner. Examples would include
agents that denature the enzyme or modulate its activity by
altering the membrane environment or that broadly modify
peptides.
For a factor to be considered a pathogenetic candidate, its
influence on the sodium pump should demonstrate reversible,
concentration-dependent inhibition acting via the cardioglycoside
binding site [20]. This study was designed to evaluate the bio-
chemical and immunological specificity of a potent inhibitor
found in the peritoneal dialysate of renal failure patients, in close
correlation with volume status and blood pressure [23]. Our first
criterion in this study, as previously described [23], was that the
responsible agent had to appear during volume expansion, and in
association with a rise in blood pressure. In this study, we have
applied a second criterion, a crucial step in the validation of the
candidacy of the agent. As opposed to the nonspecific actions
described above, a specific [Na,K]ATPase inhibitor must induce
reversible, concentration-dependent, receptor-mediated inhibi-
tion at the appropriate step in the enzyme cycle. Such an agent
would act on the cardiac glycoside or digitalis binding site. We
tested three hypotheses: (i) The effects of the PD candidate are
reversible. (ii) The PD candidate inhibits [Na,K]ATPase by an
interaction with the cardioglycoside binding site and specifically
inhibits the pump cycle by interrupting the desphosphorylation
step, analogous to all known cardioglycosides. (iii) The PD
candidate acts exclusively on [Na,K]ATPase and not on other
ATPases. We employed several assays to test each of these
hypotheses, and included ouabain and other cardioglycosides as
specific inhibitors as well, and included non-specific inhibitors,
specifically oleic acid and lysophosphatidyl choline. The results
indicate that the volume-sensitive candidate isolated from human
peritoneal dialysate acts specifically and reversibly on the sodium
pump, via the digitalis binding site.
Methods
PD candidate acquisition and purification
As described in detail earlier [23], our studies employed
peritoneal dialysate (PD) from patients with chronic renal failure,
who were maintained on chronic peritoneal dialysis, as a source
for the sodium pump inhibitor. When NaCI and water intake were
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increased for four days, the accompanying volume expansion,
evidenced in a 3 to 9 kg weight gain, was associated with a rise in
blood pressure and the appearance in plasma and in peritoneal
dialysate of a sodium pump inhibitor that was not present during
volume contraction. On processing PD [23—25], only one HPLC
fraction at 19.5 0.5 minutes elution showed an increase in
[Na,K]ATPase activity with volume shift. All of the studies on
chemical specificity that follow have been performed with this
factor.
For these studies, —2 liter PD from volume expanded individ-
uals was collected fresh the morning of each experiment. A
detailed description of its purification is provided elsewhere [231.
In brief, the dialysate was ultrafiltered through a 1000 dalton
exclusion membrane under argon. The active factor was removed
from the filtrate and volume reduced by solid phase extraction
using a preparative C18 reversed phase HPLC guard column.
After elution with 100% methanol and drying, the sodium pump
inhibitor was submitted to two C HPLC gradient fractionations.
The location of the fraction of interest was previously established
by several criteria [231. Its occurrence at 19.5 0.5 minutes
elution allowed for it to be distinguished from other inhibitors of
[Na,K]ATPase, and hence it is referred to as the PD candidate.
On completion of this purification the PD candidate was used
immediately. The amount of PD candidate thus produced varied
significantly with patient, patient state, chromatographic losses
(which were significant), and decomposition. Typically the prod-
uct of one purification was divided, from 1/5 to 1/15 being used in
a single reaction, representing 100- to 3500-fold increase in
concentration in the absence of any loss. Ouabain and digoxin
standards applied to this same HPLC system eluted at 13,5 and
23.0 minutes, respectively, and would have been completely
resolved from the PD candidate if present in PD.
Preparation of [Na,K]ATPase
[Na,K]ATPase was purified from calf kidney outer medulla as
described previously [24, 25]. Briefly, microsomes were produced
by homogenization of dissected medullary tissue followed by two
different centrifugations (10,000 X g, 30 mm and 48,000 X g, 45
mm). The pellet representing the microsomal [Na,K]ATPase was
further purified by addition of 1.4 mg!ml deoxycholate, followed
by ultracentrifugation (180,000 )< g, 110 mm) through a two-layer
discontinuous gradient of 23% and 38% sucrose. The activity
resided at the interface of the 38% and the 23% sucrose fractions.
All experiments involving [Na,KJATPase used enzyme prepared
in this manner unless otherwise noted.
Tests of the reversibility of the PD candidate's actions
Cross reactivity with digoxin antisera. Physiologic suppression of
enzyme activity is reversible, that is, does not irreversibly denature
or poison the enzyme. In the absence of a specific antagonist of
the PD candidate or cardioglycosides, the most compelling alter-
native approach is to reverse inhibition by antibody binding of the
inhibitor (immunoneutralization) with a restoration of activity. To
accomplish such experiments, the first requirement was to identify
antibodies with affinity for the PD candidate and establish a
relationship between crossreactivity and biochemical activity. Ini-
tially PD candidate cross reactivity was assessed using a digoxin
RIA (components obtained from Dupont-NEN, Billerica, MA,
USA) described in detail previously [26, 271. Purified specimens of
PD candidate from peritoneal dialysate were collected, dried,
resuspended in 10 mmol/liter sodium phosphate (pH = 7.4) and
then divided among two dilution sets. The PD candidate available
for one assay was diluted 1/2, 1/4, 1/10, 1/20, and 1/40. One set was
assayed in the [Na,K]ATPase assay described above and the other
in the digoxin RIA.
In a second set of experiments digoxin, the PD candidate,
ouabain, strophanthidin and bufalin were serially diluted and
assayed in duplicate in the same digoxin RIA. Lysophosphatidyl
choline (LPC), a non-specific sodium pump inhibitor, at concen-
trations of iO and 10—2 mol/liter was also assayed. Data are
expressed as the fraction of labeled digoxin bound to antibody for
each concentration of analyte (B) divided by the fraction of
labeled digoxin bound in the absence of analyte (B0) and plotted
as the ratio of B/B0 versus the concentration.
Immunoneutralization with digoxin antibody Fab fragment. The
previous experiments demonstrated an interaction between
digoxin antibodies and digoxin, ouabain, strophanthidin, bufalin
and the PD candidate. We then set out to extend this observation
to a digoxin antibody Fab fragment that has been effective in a
volume sensitive model [71. In the first set of experiments employ-
ing the Fab fragment, we sought to prevent an inhibitory action by
immunoneutralization. In these experiments, 20 l of the PD
candidate (N = 6), dried and resuspended in 100 p1 sodium
phosphate buffer (pH 7.4), ouabain (5 X iO mol/liter, N = 9),
bufalin (1 X i0 mol/liter, N = 6) and LPC (7 >< 10 mol/liter,N = 4, as a non-specific inhibitor and control) were incubated
with 2 X 10_6 mol/liter Fab fragments of an anti-digoxin antibody
(Digibind, Burroughs-Wellcome, Triangle Park, NC, USA; FW
—50,000) or with 1 >< 10_6 mol/liter sheep IgG in 20 /LI sodium
phosphate buffer for one hour at 37°C. After the incubation, 100
pJ of buffer A [(in mmol/liter) 100 Na, 5 K, 3 Mg and 80 Tris (pH
7.4)] containing [y-32P]ATP (final concentration 4 mmol/liter),
and 10 p1 of [Na,K]ATPase were added directly and incubated for
30 minutes at 37°C to measure ATPase hydrolytic activity. The
workup thereafter was identical to the [Na,K]ATPase assay
described below.
The second series of experiments examined the ability of the
digoxin Fab fragment to reverse the action of the PD candidate.
The inhibitor (PD candidate, N = 8) was divided into four equal
portions and each allowed to incubate with the enzyme for 30
minutes. To two of these incubations, the digoxin Fab fragment
was introduced (1 X 10 mol/liter) to determine whether the Fab
could reverse the effects of the PD candidate. In parallel experi-
ments, paired aliquots of ouabain (1 x i0 mol/liter, N = 6) and
lysophosphatidyl choline (7 X 10 mol/liter, LPC; N = 6),
included as a non-specific inhibitor control, were followed by
addition of 1 x 10 mol/liter Fab fragments to one of each pair.
The reaction for all aliquots was then started by adding
[y-32PIATP and followed the method described for the [Na,K]-
ATPase reaction. Several concentrations of ouabain were used
and compared to the mean of the PD candidate response.
Tests of the PD candidate acting specifically via the digitalis
binding site
[Na,K]ATPase assay. This assay is the one most commonly
employed by investigators to assess the PD candidate activity.
Inhibition of [Na,K]ATPase hydrolysis is a necessary but insuffi-
cient feature of any specific Na-pump inhibitor, in as much as
non-specific inhibitors (or enzyme inactivators) are common,
especially when purified [Na,K]ATPase is used [19—22, 25]. While
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a useful and important test, the assay does not assess whether an
inhibitor binds to the digitalis binding site. The activity of
[Na,KjATPase and its inhibition were determined by measuring
the hydrolysis of [y-32P]ATP. Twenty microliter aliquots of PD
candidate from a total of 300 jil or ouabain were incubated with
10 jig of enzyme for 30 minutes at 37°C in 110 p1 of Buffer A or
as specified in legends to the Figures. The hydrolysis was started
by adding 10 p1 of 40 mmol!liter [32P]ATP (final concentration 4
mmol/liter ATP) and ended after 30 minutes as described above.
Ouabain-insensitive activity was defined as the activity remaining
in the presence of 1 mmol/liter ouabain. Specimens were typically
assayed in duplicate.
Ouabain binding. The ability of compounds to inhibit ouabain
binding to [Na,K]ATPase has also been frequently used to assay
DLF. Binding to and competition for the digitalis binding site, is
an essential feature of all cardioglycosides and hence applicable to
candidates for a specific inhibitor of [Na,K]ATPase. While this
activity is an important requirement, it is not adequate. Some
compounds cause non-competitive, non-specific displacement of
labeled ouabain through more generalized effects on the enzyme,
such as an influence on the binding site microenvironment or on
protein conformation. Binding of [3H]ouabain to [Na,K]ATPase
was measured in the presence of Mg and Pi, which selectively
enhance binding of inhibitors acting via the digitalis receptor. The
enzyme (15 jig) was incubated with —1 x 10—8 mol/liter
[3H]ouabain and 40 jil of unlabeled ouabain or PD candidate (of
300 p1 total) to 200 p1 of a solution containing (in mmol/liter): 5
Mg, 5 P1 and 50 Tris (pH 7.2) for one hour at 37°C. The free
ouabain was separated from bound ouabain by centrifugation at
290,000 >< g for one hour. In parallel experiments the nonspecific
binding, determined in the presence of 1 mmol/liter cold ouabain,
was less than 5% of total radioactivity bound to the enzyme, and
was subtracted. The relatively low specific activity of the
[311]ouabain commercially available necessitated that relatively
high concentrations of ouabain were required to maintain ade-
quate counts of radioactivity. Typically the specimens were as-
sayed in duplicate.
Phosphoiylation. The enzyme cycle of the sodium pump in-
cludes an autophosphorylation step [28]. Cardioglycosides inhibit
the pump cycle via a reduction in the dephosphorylation rate of
this phosphoenzyme species (E-P) resulting in increased levels of
phosphoenzyme with cardioglycoside inhibition. This assay is
much less sensitive to non-specific inhibition of enzyme activity
and requires that a candidate operate in a fashion equivalent to all
known cardioglycosides [28]. Some consider it to be the most
specific test for a specific pump inhibitor [19, 28]. Phosphorylation
assays were carried out at 22°C for 20 seconds in the absence or
presence of inhibitor and a reaction volume of 100 pd containing
10 jig [Na,K]ATPase and (mmol/liter): 3 Mg, 150 Na, 30 imidazole
(pH 7.4) adding —-2 nmol/liter [y-32P]ATP to start the reaction.
The reaction was then terminated 20 seconds later by adding 0.5
ml of an ice-cold stopping-solution containing 10% trichioroacetic
acid, 1 mmol!liter ATP and 10 mmol/liter pyrophosphate. The
mixture was allowed to stand for 10 minutes on ice before
centrifugation. The protein was separated by centrifugation and
washed once with 0.5 ml ice-cold 10% trichloroacetic acid. The
precipitate was dissolved in 0.5 ml of 0.5% SDS and the radioac-
tivity was counted. Nonspecific binding of [32P]Pi was obtained by
addition of medium without Mg and Na and was subtracted from
total counts of radioactivity. For these experiments buffer alone
(N = 6), ouabain at concentrations of io (N = 4), 10_6 (N = 6),
and io mol/liter (N = 4), and PD candidate (N = 5) were tested.
Dephosphotylation. After phosphorylation of enzyme for 10
seconds on ice in the absence of inhibitor, the reaction was
quenched by adding 100 p1 of a solution containing 1 mmol/liter
non-radioactive ATP and PD candidate (N = 6) or ouabain (N =
6) at each of three concentrations (10—s, 10_6, and io mol/liter
or continued absence of inhibitor (as the control), and dephos-
phorylation was allowed to occur for 10 seconds (at 37°C) until the
reaction was terminated with the stopping-solution employed for
the phosphorylation assay, and the phosphoenzyme level was
determined as described above.
Tests of PD candidate specificity to [Na,K]A TPase
Inhibition of ouabain sensitive and insensitive [Na,K]ATPase
activity. Cardioglycosides exert their effects on only one enzyme,
the sodium and potassium-stimulated [Na,K]ATPase. Other
ATPases do not bind cardioglycosides nor is their activity modu-
lated by them. Hence, a simple, yet important, requirement of any
candidate for the endogenous Na-pump inhibitor is that its
inhibition be limited to [Na,K]ATPase. We used two approaches
to assess this requirement. The first took advantage of the
observation that crude calf, kidney microsomes contained both
ouabain-sensitive and insensitive ATPase activity.
Microsomes were prepared as described above. To 10 jig of
microsomes in a buffer A, a maximal inhibitory dose of ouabain (1
x i0 mol/liter) was incubated for 30 minutes at 37°C and
compared to an identical incubation omitting the ouabain. There-
after, 10 p1 of a 40 mmol/liter [y-32P]ATP solution (Amersham,
Arlington Heights, IL, USA; final specific activity —70 mCi/mol)
was added to each reaction and the hydrolysis allowed to occur for
an additional 30 minutes to determine the portion of ATPase
activity that was ouabain-sensitive, and hence represented
[Na,K]ATPase. After the incubation the reaction was terminated
by adding a known volume of a 4% charcoal/0.1 N HC1 solution.
After mixing and centrifugation (10 mm at 1200 x g), a known
aliquot of supernatant was removed and radioactivity counted. In
an attempt to identify the substrate and nature of the other
ATPase activity, in separate aliquots, thapsigargin (3.3 X 10
mol/liter), an inhibitor of microsomal Ca-ATPase [29] was added
to microsomes in the presence or absence of I X iO mol/liter
ouabain in an identical fashion. Finally, other aliquots of ouabain
at concentrations causing intermediate levels of [Na,K]ATPase
inhibition (2.5 X iO mol/liter) or maximal inhibition (1 X 10
mol/liter) were incubated in the presence or absence of PD
candidate. The inhibition produced by the other half of the PD
candidate preparation by itself was simultaneously measured.
We also performed other experiments with oleic acid, a known
non-specific inhibitor of ATPase activity, as a negative control for
specific action. Oleic acid at concentrations of 2.5 x iO and I x
i0 mol/liter was incubated with and without 1 X 1O mol/liter
ouabain and inhibition of ATPase activity assessed.
Inhibition of Na and K stimulated A TPase activity. The second
approach to insure specificity used the same crude microsomes
but now assessed [Na,K]ATPase activity by omitting Na and K,
which are requisite for its activity but are not required for other
ATPases. Specifically, 10 jig of crude microsomes were incubated
with ouabain (1 x i0 mol/liter, N = 6) or with divided
preparations of PD candidate (N = 6), half in buffer A and half in
buffer A omitting the Na and K. The procedure described above
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was followed thereafter. Oleic acid (2.5 X 10 mol/liter, N = 6,
as a non-specific ATPase inhibitor, was tested in like fashion.
Statistical analysis
Data are expressed as the mean the SEM. Comparisons
between one set of conditions and another for a single agent being
tested were statistically tested using Student's t-test. Comparisons
of several observations to a control were made by ANOVA, with
post-hoc, pair-wise comparisons using Dunnett's test. Compari-
sons of two assays employing paired observations were made by
Pearson's Product Moment Correlation test. A P-value <0.05 was
considered significant.
Results
Preparation of a volume-sensitive sodium pump inhibitor from
human peritoneal dialysate
The detailed studies that follow assessed a single sodium pump
inhibitor from PD, the activity of which increased with volume
expansion in renal failure patients on peritoneal dialysis. Only
activity in the HPLC fraction at 19.5 0.05 minutes was volume
sensitive and only this factor's activity correlated with weight
change during volume expansion, changes in blood pressure, and
the serum levels of [Na,K]ATPase inhibition [23].The location of
this volume sensitive PD candidate was well resolved from regions
of the HPLC chromatogram where ouabain (13.0 mm) or digoxin
(22.5 mm) would elute if present.
Reversibility of the PD candidate's effects
Competition of the PD candidate, ouabain, bufalin, strophan-
thidin or digoxin with ['2511-labeled digoxin for digoxin specific
antibodies was assessed, Serial dilution of single preparations of
the PD candidate or graded concentrations of the cardioglyco-
sides were assayed in a digoxin radioimmunoassay. The PD
candidate, as well as the cardioglycosides tested, showed a con-
centration-dependent reduction in the level of bound digoxin
tracer. The curve for the PD candidate was similar to the standard
curve of digoxin (Fig. 1A), but differed from other cardioglyco-
sides which tended to have flatter displacement curves (Fig. 1B).
Among the cardioglycosides, the least digoxin antibody cross
reactivity was seen with ouabain. However, LPC require concen-
trations iO mol/liter or greater to produce significant displace-
ment of labeled digoxin from the digoxin antibody (data not
shown).
To provide additional evidence that the species cross reacting
with the digoxin antiserum was the active inhibitory agent, other
specimens of the PD candidate were divided equally and assayed
both by the digoxin RIA and by inhibition of [Na,K]ATPase (Fig.
2). This comparison demonstrated a highly significant correlation
between the two assays (r = 0.95, P = 0.012).
We next examined the ability of a purified Fab fragment of
anti-digoxin IgG (Digibind) to prevent the effects of the PD
candidate, ouabain, and bufalin. A 30 minute preincubation of the
digoxin Fab with each of the three agents was found to signifi-
cantly reduce their inhibition of [Na,K]ATPase hydrolysis (Table
1). Additionally, this same Fab fragment was incubated with a
non-specific inhibitor, lysophosphatidyl choline, without a reduc-
tion in the LPC influence on [Na,K]ATPase activity (Table 1).
Physiologic Na pump inhibition, as opposed to non-specific
enzyme inactivation or denaturation, should be reversible. Hence,
10 i0 io
Concentration, mo//liter
Fig. 1. Concentration dependent digoxin RL4 response of the PD candidate
and cardioglycosides. The ratio of the label bound at a given Concentration
of antigen (B) divided by the amount of label bound in the absence of
antigen (Bo) is plotted as a function of concentration. The response to
serial dilutions of a single preparation of PD candidate ("DLF", •) or to
graded concentrations of digoxin (LI) is shown in A. Other cardioglyco-
sides, strophanthidin (+), bufalin (•), ouabain (A) were tested in a
similar fashion and are shown in B.
evaluation of candidates should include assessment of reversibil-
ity. We exploited the PD candidate's binding to digoxin antibod-
ies, and specifically to the digoxin Fab fragment, to probe
reversibility of its influence on [Na,K]ATPase. Ouabain was used
as a specific inhibitory control and LPC was used as a non-specific
inhibitory control. Each inhibitor was incubated with the enzyme
for 30 minutes under ionic conditions that favor tight specific
binding to the digitalis receptor. This was followed with a 30
minute incubation of the inhibitor-enzyme complex with Fab
fragments. As shown in Figure 3, exposure to Fab fragments after
inhibitor binding to the enzyme significantly reversed the inhibi-
tion of [Na,KJATPa5e activity produced by the PD candidate or
ouabain, but not that produced by LPC (PD candidate, N = 8,
from 7.8 2.4 to —1.1 2.0%, P = 0.006; ouabain, N = 8, from
25.4 2.6 to 3.9 1.2%, P < 0.001; LPC, N = 6, from 40.2 1.6
to 38.1 3.7%, not significant).
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Fig. 2. Relationship between the PD candidate's displacement of labeled
digoxin from digoxin antibody and to inhibit [Na,KJATPase activity. Five
individual purifications of the PD candidate were divided equally and
assayed simultaneously in both the digoxin RIA and the [Na,K]ATPase
hydrolysis assay. The line of regression is plotted. The correlation was
significant (r = 0.95, P = 0.012).
Table 1. The ability of the digoxin Fab fragment to attenuate the
inhibition induced by the PD candidate, ouabain, bufalin and
lysophosphatidyl choline
Agent
Inhibition of [Na,KIATPa5e %
PSheep IgG Dig Fab
1. PD candidate N = 10 18.5 3.3 0.2 1.4 0.0001
2. Ouabain N = 9 56.9 7.7 3.3 3.2 0.0001
3. Bufalin N = 6 60.9 4.8 3.7 2.2 0.0001
4. LPC N = 4 25.9 2.8 29.9 6.7 0.57
Paired specimens of PD candidate, ouabain (5 x i0 mol/liter), bufalin
(1 x iO mol/liter) or lysophosphatidyl choline (LPC, 7 x iO mol/liter)
were used. One was incubated in the presence of digoxin Fab fragments
(Dig Fab, 2 X 10' mol/liter) and one in the presence of non-immune
sheep IgG (1 x 10' mol/liter) prior to assessing their effects in the
[Na,KIATPase assay as described in Methods.
Fig. 3. The binding affinity of Fab for ouabain and DLF was exploited to
ascertain whether the inhibition induced by the various inhibitors was
reversible. Exposure to Fab reversed the inhibition induced by ouabain and
the PD candidate, but did not influence the inhibition due to lysophos-
phatidyl choline (LPC). [Na,KIATPa5e was preincubated with the PD-
candidate ("DLF"), ouabain (8 >< 108 mol/liter) or LPC (7 >< iO
mol/liter) for 30 minutes. Half of this incubate was employed in the
[Na,KIATPa5e assay immediately. Half was transferred into tubes con-
taining Fab at a final concentration of 10 mol/liter, and assayed 30
minutes later. < 0.01, inhibitor versus inhibitor plus Fab; **p < 0.001.
The inhibition produced by the PD candidate alone was significantly
greater than the buffer control (P < 0.01).
tions of ouabain of this level or greater and split specimens of the
PD candidate, we measured both inhibition of [Na,KIATPase
hydrolysis and the displacement of [3Hjouabain. The displace-
ment of [3Hjouabain binding by unlabeled ouabain was linearly
related to the inhibition of [Na,K]ATPase activity (r = 0.95, P <
0.0001; Fig. 4). The effect of PD-DLF on labeled ouabain binding
in relation to inhibition of [Na,K]ATPase activity was also highly
correlated (r = 0.91, P < 0.0001). The regression line (not
plotted) for the PD candidate calculated by the least squares
method paralleled that of ouabain. The results suggest a specific
inhibition of [Na,KIATPa5e mediated by the PD candidate bind-
ing to the digitalis receptor in a manner identical to ouabain.
We studied the effect of the PD candidate and ouabain on levels
of the acid-stable phosphoenzyme (E-P). Non-specific inhibitors
do not increase E-P levels [281. The PD candidate produced
significant increases in both absolute and relative amounts of
phosphorylated [Na,K]ATPase (Fig. 5A). Compared to the effects
of ouabain, the PD candidate (N = 5) showed an increase in E-P
levels which exceeded that produced by 10' mol/liter ouabain
(N = 6) but was less than that produced by 10 mol/liter ouabain(N = 4). To clarify whether the increment of E-P caused by the
PD candidate was due to increased production or to a reduction
in the rate of dephosphorylation, we also studied the action of the
PD candidate or ouabain on the stability of phosphoenzyme. The
phosphoenzyme was incubated in a medium containing the PD
candidate or ouabain with an excess of unlabeled ATP, which
prevents the enzyme relabeling. As shown in Figure SB, the
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Action via the digitalis binding site of the sodium pump
We have recently demonstrated that the PD candidate pro-
duced a concentration-dependent inhibition of [Na,KIATPase
activity with mass-action kinetics appropriate for a specific inhib-
itor with concentration response curves that paralleled those of
bufalin and ouabain [251. Both ouabain and the PD candidate
produced a concentration-dependent inhibition of labeled
ouabain binding to purified [Na,K]ATPase. We then sought to
test the interdependence of binding to the digitalis receptor and
inhibition of hydrolytic activity. This was somewhat more compli-
cated because the absolute concentration of the [3H]ouabain
solution commercially available, which was approximately 1 X
iO mol/liter, was sufficient to produce =50% inhibition of
[Na,K]ATPase hydrolysis. Nevertheless, using paired concentra-
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Fig. 4. Relationship between the inhibition of [3H] ouabain binding and its
inhibition on fNa,KJATPase activity. Serial dilutions of the PD-candidate
("DLF", •) and graded concentrations of ouabain (0) were assayed in
both the ouabain binding and [Na,KIATPa5e hydrolysis assays. The lowest
concentration of 3H-ouabain commercially available was sufficient to
inhibit —50% of hydrolysis activity. The regression line of best fit is shown
for ouabain (solid line). Data points represent the average of duplicate
determinations from four experiments, each employing a separate prep-
aration of the PD candidate.
amount of E-P remaining after 10 seconds of dephosphorylation
was much greater in the presence of the PD candidate or ouabain
than in their absence. The increment in the level of E-P in the
presence of either inhibitor was comparable to that seen in the
phosphorylation experiment (Fig. 5 A, B).
Specificity of the PD candidate for [Na,K]ATPase
Whether the PD candidate's inhibition was limited to the
[Na,K]ATPase, as opposed to other ATPases, was examined. This
was accomplished by employing calf kidney microsomes, which
have both ouabain-sensitive and -insensitive ATPase activity. The
[Na,K]ATPase activity is the only ATPase activity that is ouabain
sensitive. The first series of experiments, using a maximal inhibi-
tory concentration of ouabain (10—s mol/liter), determined that,
on average, 35 to 40% of the total ATPase activity was ouabain-
sensitive, [Na,K]ATPase activity. The combination of iO molt
liter ouabain and 3.3 X iO mol/liter thapsigargin (as an inhibitor
of microsomal Ca-ATPase), induced a 69% inhibition of all
ATPase activity, suggesting that much of this residual, non-
ouabain inhibitable activity was Ca-ATPase. When ouabain was
used at concentrations that did not produce complete inhibition of
the [Na,KIATPase, an additive effect of the PD candidate and
ouabain on the ouabain-sensitive activity was found (for example,
21% inhibition for ouabain, 32% for PD-DLF and 47% for
ouabain plus PD-DLF). When ouabain at a concentration that
induced maximal inhibition of the ouabain-sensitive, [Na,KI-
ATPase activity (1 mmoltliter) was combined with PD candidate
(half of which produced significant inhibition) no further inhibi-
tion was seen. Hence, the PD candidate acts on the same fraction
of ATPase activity as is ouabain-sensitive (Table 2). In contrast,
oleic acid when added to 1 mmol/liter ouabain, produced signif-
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Fig. 5. Effect of the PD candidate or ouabain on the level of acid stable
phosphoenzyme (E-P). In the first set of experiments (A), the level of
[Na,KIATPase phosphorylation product was measured after 20 seconds
(22°C) in the presence of Mg, physiologic Na (pH 7.4) and [32PIATP and
inhibitor, either PD candidate ("DLF", ) orouabain () at graded doses
and compared to control (CTL) incubations omitting inhibitor (LI). The
second set of experiments measured dephosphorylation rate (B). After
phosphorylation in the presence of Mg, Na, and r2P] for 10 seconds, (4°C)
dephosphorylation was initiated by adding 1 x i0 mol/liter cold ATP in
combination with either the PD candidate (DLF) or ouabain at graded
doses and allowed to continue for 10 seconds (37°C) and compared to
CTL incuhations omitting the inhibitor (LI). An asterisk denotes a
phosphoenzyme significantly greater than control (P < 0.01). Ouabain
induced the anticipated, concentration-dependent influence of phosphor-
ylation. The PD candidate had a similar influence, with a relative activity
that lay between ouabain at 10 and iO mol/liter. Data represent 4 to
6 determinations for ouabain and five for the PD candidate.
icantly more inhibition (44.8%) compared to maximal ouabain by
itself (32.6%; Table 2).
The ionic requirement for the PD candidate inhibition of
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Table 2. Specificity of the PD candidate or oleic acid for ouabain-
sensitive [Na,K]ATPase
Agent
Inhibition of total ATPase activity %
Agent only QUA QUA + agent
DLF N = 3 18.6 6.8 39.3 3.7 35.7 3.5
Oleic acid N = 5 22.7 5.1 32.6 1.3 44.8 3.8a
Kidney microsomes, containing both INa,K]ATPase and Ca-ATPase,
were incubated with ouabain (QUA) at a concentration sufficient to
inhibit all the fNa,K]ATPase (1 mmol/liter) or with another agent,
PD-candidate (DLF) or oleic acid, as a non-specific inhibitor. At the same
time we assessed the additive effects of the other half of the split PD
candidate preparation or oleic acid in combination with 1 mmol/liter
ouabain. 'P < 0.05 for the additive effect of the agent and ouabain being
greater than I mmol/liter ouabain alone. The PD candidate acts only on
the ouabain sensitive, [Na,KIATPa5e whereas oleic acid, has effects on
other ATPase activity as well.
[Na,K]ATPase is shown in Figure 6. In the paired experiments,
PD candidate produced no significant inhibition in the absence of
Na and K (0.4 1.1%, N = 6). This was significantly less than the
inhibition produced by the other half of the PD candidate when
tested in the same medium containing Na and K (6.0 1.6, P <
0.001). This pattern was equivalent to that found for 1 X iO
mol/liter ouabain (0.0 3.7 vs. 18.9 0.5%, P < 0.01, N = 6).
Oleic acid (2.5 >< I0 mol/liter) produced significant inhibition in
the absence of Na and K (12.9 1.0%, N = 6), and the presence
of Na and K in the medium did not alter the level of inhibition it
produced (14.5 1.3%, P = 0.40).
Discussion
Hypertension in end-stage renal disease is common and influ-
enced substantially by volume status [1, 2]. The agent in this study
is found in the peritoneal dialysate in concentrations adequate for
measurement only when the patient is volume expanded, a
criterion we consider crucial for candidacy [20]. One of the major
problems in this field has been the large number of agents
suggested as candidates based not only on a minimal number of
criteria, but often on criteria that were rather nonspecific [19—22].
Because no one test is definitive for a true sodium pump inhibitor,
this study employed a range of criteria to examine the specificity
of the PD candidate [23]. First, because several inhibitors appear
to act by a nonspecific denaturing or "detergent" effect, we
examined the reversibility of the PD candidate's action. To do so,
we exploited the high binding affinity of the PD candidate and
other cardioglycosides for an Fab developed for digoxin. The PD
candidate caused an inhibition of [Na,K]ATPase that was fully
reversible following immunoneutralization with the Fab. Likewise
there was strong concordance between the PD candidate's affinity
for a digoxin antiserum and functional activity. Our second goal
was to establish whether or not the PD candidate acted specifically
at the digitalis-binding site. The PD candidate was shown to
compete with labeled ouabain for the digitalis binding site, and
that pump inhibition was highly correlated with this binding. We
also examined the influence of the PD candidate on the phos-
phorylation-dephosphorylation step of the Na pump cycle. Digi-
talis glycosides inhibit the pump's dephosphorylation step, allow-
ing accumulation of the phosphorylated enzyme. In this study,
that action was confirmed and extended to the PD candidate,
whose activity exceeded that of ouabain at 10 mol/liter, but was
Fig. 6. The influence of sodium and potassium on fNa,KJATPase inhibition
induced by the PD candidate, ouabain or oleic acid. Paired specimens of
ouabain (10—v mol/liter), the PD candidate ("DLF"), and oleic acid (2.5 x
iO mol/liter) as a non-specific control were incubated with the enzyme
in the presence (LII) or absence () of sodium plus potassium and ATP
hydrolysis measured. *P < 0.01. The inhibition induced by PD candidate
in the presence of Na and K was significant compared to omitting it (P <
0.01). Note that DLF shares with ouabain the requirement for sodium and
potassium to induce ATPase inhibition, whereas oleic acid did not.
less active than ouabain at iO mol/liter. Finally, we sought to
establish that the PD candidate's influence was limited to [Na,K]-
ATPase. We found that sodium and potassium were required for
the PD candidate to cause inhibition, and it demonstrated no
influence on other ATPase activity. As non-specific controls, we
employed agents suggested earlier as possible candidates, oleic
acid and LPC. As anticipated, both agents failed to satisfy these
criteria.
Another suggested candidate, ouabain, was also examined in
this study. Evidence in this study and elsewhere [23] indicates that
the PD candidate differs chemically from ouabain.
Multiple regions of [Na,K]ATPase inhibition were observed in
the concentrated HPLC eluate of PD [23]. For this reason, we
developed a clinical protocol in which patients gradually expanded
their extracellular volume and concomitantly their blood pressure.
By comparing the level of sodium pump inhibition in each HPLC
fraction before, during and after volume expansion, we were able
to identify a single HPLC fraction that correlated closely with the
volume shift. This same HPLC fraction was also the only region
that was correlated with serum [Na,K]ATPase inhibitory activity
and to the patient's increase in blood pressure. As such the first
criterion for candidacy—a clinical or physiological correlation—
was satisfied [20]. This volume sensitive factor possessed a con-
sistent retention time on HPLC distinct from cardioglycosides and
other candidates and was termed the "PD candidate" to avoid
confusion.
We and others [26, 27] have used digoxin antisera to study
digoxin-like factors on the premise that a digoxin antibody may
recognize the endogenous ligand if structurally similar. The
specificity of commercial digoxin antisera is very high for digoxin,
modest for other cardiac glycosides, and low for steroid hormones
and other compounds. Therefore, a digoxin radioimmunoassay
might prove useful in the search for the endogenous inhibitor. The
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PD candidate competed with labeled digoxin for the digoxin
antibodies with a concentration dependence that paralleled
digoxin. Other cardioglycosides (ouabain, strophanthidin, and
bufalin) demonstrated a concentration-dependent displacement
of labeled digoxin from the antibody with a slope that differed
significantly from the digoxin or the PD candidate. These exper-
iments also revealed that the amount of the PD candidate causing
a 50% displacement of labeled tracer from digoxin antibody
produced 57% inhibition of [Na,KJATPase, whereas a concentra-
tion of ouabain causing 50% displacement of digoxin tracer
caused more than 95% inhibition (data not shown), suggesting a
much higher cross reactivity for the PD candidate than ouabain,
and perhaps also explaining the different response curves. Digoxin
antisera do not measure functional activity, and since some
researchers had found no association between digoxin-like immu-
noreactivity and inhibition of [Na,K]ATPase [14], the digoxin-like
cross reactivity of the PD candidate was compared to [Na,K]-
ATPase inhibition. This revealed a marked correlation, indicating
the inhibition was proportional to its cross reactivity, and sug-
gested strongly that the PD candidate, an active inhibitor, is also
recognized by the antibody. Because it was possible that two
agents co-eluted on HPLC, each active in only one assay, we
employed other experiments.
Having evidence for an interaction between our inhibitor and
the digoxin antibody, we wanted to confirm that finding by using
a digoxin antibody to interrupt the PD candidate's inhibition of
[Na,K]ATPase activity. To do this we chose purified Fab frag-
ments of a digoxin antiserum (Digibind) for two reasons. First, the
absence of other serum components ensured that interactions
seen represented PD candidate binding to the Fab. Second, if the
Fab produced the anticipated effect, it provided a preparation
more suitable than whole anti-digoxin antiserum with which to
attempt in vivo experiments [7]. Digoxin Fab neither influenced
[Na,K]ATPase activity by itself, nor did it influence the inhibition
produced by LPC, a non-specific inhibitor. In contrast, in parallel
experiments, Fab fragment preincubation with the PD candidate
or ouabain completely blocked their inhibition of [Na,K]ATPase,
presumably by binding the inhibitors. This observation is in
agreement with in vitro and in vivo studies [7, 30—32].
Having confirmed an interaction of the PD candidate with the
digoxin Fab, we had a probe with which to "neutralize" the PD
candidate's effects. We then demonstrated that PD candidate or
ouabain-induced inhibition of [Na,KJATPase was rapidly reversed
by a 30 minute incubation with the digoxin Fab fragment. In
marked contrast, LPC-induced inhibition was not affected by Fab
treatment. If it is to serve as a physiological regulator, the
endogenous inhibitor's action on the cardioglycocide receptor
should be reversible. Digoxin Fab reversal of pre-established
binding of the PD candidate to [Na,K]ATPase with consequent
reversal of inhibition is consistent with such an action and our first
hypothesis. A similar finding has been reported by Baizan et a!,
who studied a partially purified candidate from cord blood [31].
Binding of cardioglycosides to their receptor has been exten-
sively studied and the characteristics shown to be very specific.
Hence, we assumed that a candidate's response to binding condi-
tions should be identical to the cardioglycosides if it occupies the
same site. Recently we demonstrated that the PD candidate
binding and subsequent inhibition were amplified by a pre-
reaction environment high in Mg and Pi, responses limited to
cardioglycosides [24, 25], providing support for an action at the
same binding site.
The PD candidate reduced [3H]ouabain binding to its receptor
in a concentration depndent manner, and inhibition of [Na,K]-
ATPase hydrolysis was highly correlated to this binding, in
parallel with ouabain. This provided additional evidence that the
PD candidate and ouabain share the same binding site and that
[Na,K]ATPase inhibition depends on this binding. However nei-
ther of these approaches examines the mechanism of inhibition. A
rigorous criterion demanded that we establish that the PD
candidate induced inhibition at the same state of the enzyme cycle
as known cardioglycosides.
During the Na pump cycle, the enzyme is phosphorylated by
ATP in the presence of Mg and Na and then dephosphorylated in
the presence of K. In vitro, the isolated enzyme can also be
phosphorylated in reverse, starting with Mg+Pi. The phosphory-
lation of [Na,K]ATPase from Pi in the presence of Mg is increased
by cardioglycosides by way of a mechanism that involves reduced
dephosphorylation [33, 34]. The concentration dependence of Na
pump inhibitors on phosphoenzyme level and on inhibition of
[Na,KIATPase activity is roughly the same [34]. This promotion of
32p incorporation from Pi into [Na,K]ATPase has been suggested
to be the most rigorous criterion for classifying a compound as
truly digitalis-like, and that approach has been confirmed [19, 28].
The influence of cardioglycosides on the phosphoenzyme level in
the presence of Na, Mg and ATP is more complex. Some studies
report enzyme phosphorylation from ATP being completely pre-
vented by ouabain [36, 37], while others showed no ouabain effect
[38]. The available data suggests that ouabain's effect on phos-
phorylation varies with temperature, ATP concentration, sodium
concentration and the ionic strength of the medium [39, 40]. In
this study the PD candidate, like ouabain, produced a significantly
increased level of phosphoenzyme in the presence of Mg, Na and
ATP, suggesting that it acts via the same binding site and
mechanism. The dephosphorylation rate of phosphoenzyme was
also measured. As expected, the PD candidate increased phos-
phoenzyme as a result of a reduction of the dephosphorylation
rate, as seen with cardioglycosides [34, 40, 41]. The ability of the
PD candidate, like ouabain, to stabilize phosphoenzyme, not only
from Pi but also from ATP, suggests that specific inhibition of
[Na,K]ATPase is due primarily to a prolonged half life of the
enzyme-inhibitor complex, which cannot be rephosphorylated by
ATP, and thereby interrupts the pump cycle. The exacting con-
straints of these observations support the contention that this
approach discriminates true candidates from other [Na,KIATPa5e
inhibitors [19, 28], and the findings conform well with our second
hypothesis.
To determine whether the PD candidate produced inhibition
limited to the [Na,KIATPase and does not extend to other
ATPases, we took advantage of an unpublished observation:
Bovine renal microsomal ATPase activity was only partially
inhibited by ouabain (35 to 45% of total activity) at a concentra-
tion sufficient to inhibit all [Na,K]ATPase, suggesting the presense
of ATPase activity unrelated to the sodium pump. In agreement,
thapsigargin, a specific inhibitor of intracellular Ca-ATPase [29],
blocked 47% of total ATPase activity, and when ouabain and
thapsigargin were used together, a marked additive inhibition was
measured (69% of total). Therefore, both [Na,KIATPase and
Ca-ATPase were present. Oleic acid, a non-specific inhibitor,
produced an inhibition of ATPase which significantly exceeded
428 Tao et a!: Specific pump inhibitor
that seen with high ouabain concentrations, that is, it inhibited
both the [Na,K]ATPase and other ATPases. The PD candidate
inhibited [Na,K]ATPase, and its effects were additive to those of
ouabain, when ouabain was present at a submaximal concentra-
tion. However, the PD candidate did not effect ouabain-insensi-
tive ATPase activity, that is, it did not produce further inhibition
when added to a maximal inhibitory concentration of ouabain.
While these experiments were consistent with our hypothesis, the
heterogeneity of the microsome preparation might be open to
other interpretation. Therefore, in a second series of experiments
we assessed the Na and K dependence of the PD candidate's
activity. Again oleic acid, as a non-specific inhibitor, produced an
inhibition of ATPase activity that did not require Na and K,
whereas both ouabain and the PD candidate produced inhibition
only in the presence of Na and K. Together these two experiments
support our third hypothesis.
Although the PD candidate has an action on the sodium pump
indistinguishable from all known cardioglycosides, it displays a
number of physical-chemical differences. Perhaps the most strik-
ing and important is its chemical lability [421. While many
compounds may enter the organism through the diet and accu-
mulate in the patient with renal failure, the marked lability of the
PD candidate makes this unlikely. In addition, we controlled diet
over the course of the study. Only fluid and salt intake were
modified. In addition, the HPLC gradient employed in these
experiments separates our factor cleanly from most other candi-
dates, including ouabain, digoxin, bufalin, and the common
steroid hormones [43]. Finally, when we employed an antiserum
directed against digoxin, the interaction of the PD candidate and
the antibody resembled that of digoxin far more closely than did
not only ouabain, but also strophanthidin and bufalin.
In summary, these experiments provide consistent and compel-
ling evidence that the labile PD candidate, shown previously to be
correlated with volume status, blood pressure and serum levels of
[Na,K]ATPase inhibition, also acts specifically on the sodium
pump, binding to the digitalis-binding site, and reversibly inhibit-
ing the sodium pump cycle in a manner identical to known
cardioglycosides. Thus, it fulfills important and rigorous criteria
for candidacy as an endogenous sodium pump inhibitor.
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